Abstract Details

Title “Needle Phobia” in Patients with Parkinson’s Disease (PD) Experiencing OFF Episodes is Uncommon

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 063

Objective To evaluate PD patient’s willingness to self-inject to reduce OFF episodes.

Background OFF episodes occur in majority of PD patients negatively impacting their daily life. Subcutaneous injections of apomorphine hydrochloride have been shown to reduce OFF episodes with a rapid onset of action. Other products are currently in development for the treatment of motor fluctuations requiring continuous subcutaneous infusion. There is a general perception among patients, caregivers, and physicians that patients may be unwilling to inject themselves due to needle phobia. We hypothesized that most patients will be willing to self-inject if they understand the significant benefit associated with injection.

Design/Methods We administered a questionnaire using a database of 10,578 PD patients, their next of kin, and caregivers. Responses were analyzed as percentages.

Results A total of 72.2% (7633/10578) of participants who indicated that the patient was currently taking some form of levodopa were included in the analysis. A total of 53.2% (4063/7633) of responders indicated that OFF time was a problem for the patient. Of those, 89% (3615/4063) answered “yes” to the question “During OFF times, would the patient be willing to consider using a pen device to get moving again?” Among participants who indicated the patient’s willingness to use a pen device, 68.9% were patients and 31.1% were next of kin or caregivers; 64.5% indicated that the patient had been diagnosed with PD for ≥7 years; and 39.6%, 21.2%, 20.7%, 13.2%, and 1.9% indicated that the patient was currently taking dopamine agonists, MAO-B inhibitors, amantadine, COMT inhibitors, and APOKYN, respectively.

Conclusions This survey demonstrates that 89% of patients with problematic OFF episodes would be willing to self-inject, when there is an associated benefit. Physicians may be overestimating the extent of “needle phobia.” Discussion of invasive therapies requiring injection is appropriate with most patients who have troublesome OFF time.

Authors/Disclosures
Aldina Imamovic (Rocky Mountain Movement Disorders Center) PRESENTER	Aldina Imamovic has nothing to disclose.
	No disclosure on file
Chandrasekhar Kasibhatla	No disclosure on file
Rajeev Kumar, MD, FRCPC	The institution of Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Teva Pharmaceuticals. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Annexon. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda Therapeutics. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevel Therapeutics. Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cerevance. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ferrer. Dr. Kumar has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Supernus. The institution of Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Kumar has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Research Catalyst, LLC. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for CenExel RMCR. Dr. Kumar has stock in Research Catalyst, LLC. Dr. Kumar has stock in CenExel. Dr. Kumar has stock in Neurofold Therapeutics. The institution of Dr. Kumar has received research support from Supernus. The institution of Dr. Kumar has received research support from Sage Therapeutics. The institution of Dr. Kumar has received research support from Prilenia Therapeutics. The institution of Dr. Kumar has received research support from Roche. The institution of Dr. Kumar has received research support from Triplet Therapeutics. The institution of Dr. Kumar has received research support from CHDI Foundation. The institution of Dr. Kumar has received research support from Neurocrine Biosciences. The institution of Dr. Kumar has received research support from Biovie. The institution of Dr. Kumar has received research support from Neuroderm. The institution of Dr. Kumar has received research support from Sanofi. The institution of Dr. Kumar has received research support from Addex Pharma. The institution of Dr. Kumar has received research support from Integrative Research Laboratories. The institution of Dr. Kumar has received research support from Takeda Pharmaceuticals. The institution of Dr. Kumar has received research support from Neuraly. The institution of Dr. Kumar has received research support from Abbvie. The institution of Dr. Kumar has received research support from Cerevel Therapeutics. The institution of Dr. Kumar has received research support from Transposon Therapeutics. The institution of Dr. Kumar has received research support from Lundbeck. The institution of Dr. Kumar has received research support from Biohaven. The institution of Dr. Kumar has received research support from Revance Therapeutics. The institution of Dr. Kumar has received research support from Impax Laboratories. The institution of Dr. Kumar has received research support from CND Life Sciences. The institution of Dr. Kumar has received research support from Neuron23. The institution of Dr. Kumar has received research support from Annexon Biosciences. The institution of Dr. Kumar has received research support from Annovis. The institution of Dr. Kumar has received research support from PTC Therapeutics. The institution of Dr. Kumar has received research support from Uniqure. The institution of Dr. Kumar has received research support from Alexza. The institution of Dr. Kumar has received research support from SparkNeuro. The institution of Dr. Kumar has received research support from Praxis. The institution of Dr. Kumar has received research support from Scion Neurostim. The institution of Dr. Kumar has received research support from Cognition Therapeutics. The institution of Dr. Kumar has received research support from Eli Lilly. The institution of Dr. Kumar has received research support from Aribio. The institution of Dr. Kumar has received research support from Biogen. The institution of Dr. Kumar has received research support from Bial R and D investments. The institution of Dr. Kumar has received research support from Ono Pharmaceutical Company. The institution of Dr. Kumar has received research support from UCB Biopharma. The institution of Dr. Kumar has received research support from Vigil Therapeutics. Dr. Kumar has received personal compensation in the range of $100,000-$499,999 for serving as a Medical Director with CenExel RMCR. Dr. Kumar has received personal compensation in the range of $1,000,000+ for serving as a Managing Member with Research Catalyst, LLC. Dr. Kumar has a non-compensated relationship as a Board Member with Movement Disorders Foundation that is relevant to �鶹��ýӳ�� interests or activities.

�鶹��ýӳ��

�鶹��ýӳ��